We thus reasoned that in vivo inhibition of PD-L1 plus TGF-β could be used as an experimental model to identify genes important for immune cell infiltration and anti-tumor response, and this information could be used to uncover strategies to overcome resistance to anti-PD-L1 therapy. The gene discussed is CD274; the disease is neoplasm.